The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...
The dyad model fosters collaboration between academic specialists and community oncologists, ensuring seamless patient care ...
Yuman Fong, MD, discusses the evolution of colorectal liver metastases management from historical neglect to multimodal ...
Michael David Chuong, MD, discusses how SBRT has become a leading option for treating patients with colorectal liver ...
Racial and ethnic disparities in pancreatic cancer treatment and survival persist, with minority groups experiencing lower ...
Gastrointestinal (GI) Cancers Symposium, Dani Castillo, MD, medical oncologist, City of Hope, shared new research titled, “Impact of metastatic sites and Lauren subtype on survival outcomes of ...
Zanidatamab shows promise in extending survival for patients with HER2-positive biliary tract cancer, marking a significant ...
With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...
Amid the many barriers to optimal influenza vaccination coverage, Marco del Riccio, MD, of the University of Florence in Italy, emphasizes the importance of prioritizing patients at the highest risk, ...
With Johnson & Johnson’s participation, 15 of 17 companies contacted by the administration over the summer have now signed on ...
The Trump administration's health policy changes emphasized market-driven approaches, including Medicaid work requirements ...
Elena Elimova, MD, shares efficacy data for zanidatamab in patients with HER2-positive gastroesophageal adenocarcinoma from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback